An observational study in Atrial Fibrillation, sponsored by University of Luebeck. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-07-02.
Sponsored by University of Luebeck · Observational
24 hour Holter monitoring (24HM) is commonly used to assess cardiac rhythm after surgical therapy of atrial fibrillation. This "snapshot" rhythm documentation leaves a large diagnostic window of non recorded atrial arrhythmias and as such a large amount of uncertainty in follow-up result assessment. To improve accuracy of rhythm surveillance thus gaining a more "real-life" scenario of post surgical ablation therapy cardiac rhythm a new insertable cardiac rhythm monitor device (Reveal® XT 9525, Medtronic Inc., Minneapolis, MN, USA) with full observational continuous heart rhythm documentation is implanted.
In order to verify different follow-up strategies after surgical atrial fibrillation therapy, a comparison of different follow-up scenarios (symptoms, different cardiac documentation devices i.e. ECG and 24 hour Holter monitor, at different follow-up time points) is performed intraindividually. Thus the reliability of these devices and follow-up strategies to define success after ablation therapy is evaluated.
3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.
This study's planned enrollment of 100 is below the median of 300 across 1,363 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →University of Luebeck is the lead sponsor of 74 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients who are scheduled for cardiac surgery and who also present with any kind of atrial fibrillation.
Exclusion Criteria:
Patients in atrial fibrillation being scheduled for cardiac surgery and concomitant ablation procedure
Procedure: Cardiac rhythm monitor implantation · Device: Reveal® XT 9525
post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy
Also known as: Reveal® XT 9525, Medtronic Inc., Minneapolis, MN, USA
During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
Atrial fibrillation burden development after surgical ablation therapy
Time frame: 3 years
Comparison of different cardiac rhythm documentation strategies to define success after ablation therapy
Time frame: 3 years
This study is status unknown, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Luebeck